{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T12:36:48Z","timestamp":1648989408728},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,3,25]],"date-time":"2015-03-25T00:00:00Z","timestamp":1427241600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologe"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s00120-015-3774-7","type":"journal-article","created":{"date-parts":[[2015,3,23]],"date-time":"2015-03-23T11:03:34Z","timestamp":1427108614000},"page":"491-498","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Das nicht-muskelinvasive High-grade-Harnblasenkarzinom"],"prefix":"10.1007","volume":"54","author":[{"given":"G.","family":"Gakis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Stenzl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Horn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.E.","family":"Gschwend","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Otto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,3,25]]},"reference":[{"key":"3774_CR1","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1007\/s00120-014-3585-2","volume":"53","author":"Steffens","year":"2014","unstructured":"Steffens S, Schrader AJ, Lehmann R et al (2014) Visual diagnosis while performing transurethral resection of bladder tumors: power or myth? Urologe A 53(11):1639\u20131643","journal-title":"Urologe A"},{"key":"3774_CR2","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2013.06.003","volume":"64","author":"Babjuk","year":"2013","unstructured":"Babjuk M, Burger M, Zigeuner R et al (2013) European Association of Urology. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 64(4):639\u2013653","journal-title":"Eur Urol"},{"key":"3774_CR3","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.eururo.2009.09.024","volume":"57","author":"Fritsche","year":"2010","unstructured":"Fritsche HM et al (2010) Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol 57(2):300\u2013309","journal-title":"Eur Urol"},{"key":"3774_CR4","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s00120-014-3442-3","volume":"53","author":"Hartmann","year":"2014","unstructured":"Hartmann A, Schlomm T, Bertz S et al (2014) Prognostic and predictive molecular markers for urologic cancers. Urologe A 53(4):491\u2013500","journal-title":"Urologe A"},{"key":"3774_CR5","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","volume":"49","author":"Sylvester","year":"2006","unstructured":"Sylvester RJ et al (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49(3):466\u2013505","journal-title":"Eur Urol"},{"key":"3774_CR6","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.juro.2011.09.023","volume":"187","author":"Todenh\u00f6fer","year":"2012","unstructured":"Todenh\u00f6fer T, Hennenlotter J, Witstruk M et al (2012) Influence of renal excretory function on the performance of urine-based markers to detect bladder cancer. J Urol 187(1):68\u201373","journal-title":"J Urol"},{"key":"3774_CR7","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.urolonc.2011.10.011","volume":"31","author":"Todenh\u00f6fer","year":"2013","unstructured":"Todenh\u00f6fer T, Hennenlotter J, Tews V et al (2013) Impact of different grades of microscopic hematuria on the performance of urine-based markers for the detection of urothelial carcinoma. Urol Oncol 31(7):1148\u20131154","journal-title":"Urol Oncol"},{"key":"3774_CR8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00432-012-1297-9","volume":"139","author":"Todenh\u00f6fer","year":"2013","unstructured":"Todenh\u00f6fer T, Hennenlotter J, Aufderklamm S et al (2013) Individual risk assessment in bladder cancer patiens based on a multi-marker panel. J Cancer Res Clin Oncol 139(1):49\u201356","journal-title":"J Cancer Res Clin Oncol"},{"key":"3774_CR9","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1002\/ijc.24258","volume":"124","author":"Savic","year":"2009","unstructured":"Savic S, Zlobec I, Thalmann GN et al (2009) The prognostic value of cytology and fluorescence in-situ hybridization in the follow-up of non-muscle invasive bladder cancer after intravesical Bacillus-Calmette-Guerin therapy. Int J Cancer 124(12):2899\u20132904","journal-title":"Int J Cancer"},{"key":"3774_CR10","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/cncy.20168","volume":"119","author":"Galv\u00e1n","year":"2011","unstructured":"Galv\u00e1n AB, Salido M, Espinet B et al (2011) A multicolor fluorescence in situ hydrization assay: a monitoring tool in the surveillance of patients with a history of non-muscle-invasive urothelial cell carcinoma: a prospective study. Cancer Cytopathol 119(6):395\u2013403","journal-title":"Cancer Cytopathol"},{"key":"3774_CR11","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.eururo.2012.08.061","volume":"63","author":"Burger","year":"2013","unstructured":"Burger M, Oosterlinck W, Konety B et al (2013) ICUD-EAU International Consultation on Bladder Cancer 2012: non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 63(1):36\u201344","journal-title":"Eur Urol"},{"key":"3774_CR12","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.eururo.2013.03.059","volume":"64","author":"Burger","year":"2013","unstructured":"Burger M, Grossman HB, Droller M et al (2013) Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol 64(5):846\u2013854","journal-title":"Eur Urol"},{"key":"3774_CR13","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/MOU.0b013e32833cc9f4","volume":"20","author":"Gakis","year":"2010","unstructured":"Gakis G, Kruck S, Stenzl A (2010) Can the burden of follow-up in low-grade noninvasive bladder cancer be reduced by photodynamic diagnosis, perioperative instilations, imaging, and urine marker? Curr Opin Urol 20(5):388\u2013392","journal-title":"Curr Opin Urol"},{"key":"3774_CR14","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1089\/end.2011.0042","volume":"25","author":"Fritsche","year":"2011","unstructured":"Fritsche HM, Otto W, Eder F et al (2011) Water-jet-aided transurethral dissection of urothelial carcinoma: a prospective clinical study. Endourol 25(10):1599\u20131603","journal-title":"Endourol"},{"key":"3774_CR15","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1007\/s00464-011-1627-z","volume":"25","author":"Park","year":"2011","unstructured":"Park YM, Cho E, Kang HY, Kim JM (2011) The effectiveness and safety of endoscopic submucosal dissection compared with endoscopic mucosal resection for early gastric cancer: a systematic review and metaanalysis. Surg Endosc 25:2666\u20132677","journal-title":"Surg Endosc"},{"key":"3774_CR16","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.juro.2014.06.083","volume":"193","author":"Engilbertsson","year":"2015","unstructured":"Engilbertsson H, Aaltonen KE, Bj\u00f6rnsson S et al (2015) Transurethral bladder tumor resection can cause seeding of cancer cells into the bloodstream. J Urol 193(1):53\u201357","journal-title":"J Urol"},{"key":"3774_CR17","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","volume":"49","author":"Sylvester","year":"2006","unstructured":"Sylvester RJ, Meijden AP van der, Oosterlinck W et al (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49(3):466\u2013477","journal-title":"Eur Urol"},{"key":"3774_CR18","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/00365590510031219","volume":"39","author":"Mikulowski","year":"2005","unstructured":"Mikulowski P, Hellsten S (2005) T1 G1 urinary bladder carcinoma: fact or fiction? Scand J Urol Nephrol 39(2):135\u2013137","journal-title":"Scand J Urol Nephrol"},{"key":"3774_CR19","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/j.1464-410X.2010.09515.x","volume":"107","author":"Otto","year":"2011","unstructured":"Otto W, Denzinger S, Fritsche HM et al (2011) The WHO classification of 1973 is more suitable than the WHO classification of 2004 for predicting survival in pT1 urothelial bladder cancer. BJU Int 107(3):404\u2013408","journal-title":"BJU Int"},{"key":"3774_CR20","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.eururo.2009.03.052","volume":"57","author":"May","year":"2010","unstructured":"May M, Brookman-Amissah S, Roigas J et al (2010) Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 World Health Organisation classifications. Eur Urol 57(5):850\u2013858","journal-title":"Eur Urol"},{"key":"3774_CR21","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0022-5347(05)64044-X","volume":"169","author":"Shahin","year":"2003","unstructured":"Shahin O, Thalmann GN, Rentsch C et al (2003) A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J Urol 169(1):96\u2013100","journal-title":"J Urol"},{"key":"3774_CR22","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/1097-0142(19900801)66:3<543::AID-CNCR2820660323>3.0.CO;2-R","volume":"66","author":"Younes","year":"1990","unstructured":"Younes M, Sussman J, True LD (1990) The usefulness of the level of the muscularis mucosae in the staging of invasive transitional cell carcinoma of the urinary bladder. Cancer 66(3):543\u2013548","journal-title":"Cancer"},{"key":"3774_CR23","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/j.1365-2559.2011.03989.x","volume":"59","author":"Bertz","year":"2011","unstructured":"Bertz S, Denzinger S, Otto W et al (2011) Substaging by estimating the size of invasive tumour can improve risk stratification in pT1 urothelial bladder cancer-evaluation of a large hospital-based single-centre series. Histopathology 59(4):722\u2013732","journal-title":"Histopathology"},{"key":"3774_CR24","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/00000478-200007000-00009","volume":"24","author":"Jimenez","year":"2000","unstructured":"Jimenez RE, Gheiler E, Oskanian P et al (2000) Grading the invasive component of urothelial carcinoma of the bladder and its relationship with progression-free survival. Am J Surg Pathol 24(7):980\u2013987","journal-title":"Am J Surg Pathol"},{"key":"3774_CR25","first-page":"609","volume":"12","author":"Kr\u00fcger","year":"2004","unstructured":"Kr\u00fcger S, Noack F, B\u00f6hle A, Feller AC (2004) Histologic tumor growth pattern is significantly associated with disease-related survival in muscle-invasive transitional cell carcinoma of the urinary bladder. Oncol Rep 12(3):609\u2013613","journal-title":"Oncol Rep"},{"key":"3774_CR26","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1080\/00365590902854354","volume":"43","author":"Denzinger","year":"2009","unstructured":"Denzinger S, Burger M, Fritsche HM et al (2009) Prognostic value of histopathological tumour growth patterns at the invasion front of T1G3 urothelial carcinoma of the bladder. Scand J Urol Nephrol 43(4):282\u2013287","journal-title":"Scand J Urol Nephrol"},{"key":"3774_CR27","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2013.06.003","volume":"64","author":"Babjuk","year":"2013","unstructured":"Babjuk M, Burger M, Zigeuner R et al (2013) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 64(4):639\u2013653","journal-title":"Eur Urol"},{"key":"3774_CR28","first-page":"CD006885","volume":"5","author":"Shang","year":"2011","unstructured":"Shang PF, Kwong J, Wang ZP et al (2011) Intravesical bacillus Calmette-Guerin versus epirubicin for Ta and T1 bladder cancer. Cochrane Database Syst Rev 5:CD006885","journal-title":"Cochrane Database Syst Rev"},{"key":"3774_CR29","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","volume":"56","author":"Malmstrom","year":"2009","unstructured":"Malmstrom PU, Sylvester RJ, Crawford DE et al (2009) An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur Urol 56(2):247\u2013256","journal-title":"Eur Urol"},{"key":"3774_CR30","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","volume":"168","author":"Sylvester","year":"2002","unstructured":"Sylvester RJ, van der Meijden AP, Lamm DL et al (2002) Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168(5):1964\u20131970","journal-title":"J Urol"},{"key":"3774_CR31","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","volume":"57","author":"Sylvester","year":"2010","unstructured":"Sylvester RJ, van der Meijden AP, Witjes JA, Kurth K (2010) Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 57(5):766\u2013773","journal-title":"Eur Urol"},{"key":"3774_CR32","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.eururo.2014.05.033","volume":"66","author":"Oddens","year":"2014","unstructured":"Oddens JR, Sylvester RJ, Brausi MA et al (2014) The effect of age on the efficacy of maintenance bacillus calmette-guerin relative to maintenance epirubicin in patients with stage ta t1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911. Eur Urol 66(4):694\u2013701","journal-title":"Eur Urol"},{"key":"3774_CR33","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/j.1464-410X.2012.11390.x","volume":"111","author":"Houghton","year":"2013","unstructured":"Houghton BB, Chalasani V, Hayne D et al (2013) Intravesical chemotherapy plus bacille Calmette-Guerin in non-muscle invasive bladder cancer: a systematic review with meta-analysis. BJU Int 111(6):977\u2013983","journal-title":"BJU Int"},{"key":"3774_CR34","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.eururo.2014.02.061","volume":"66","author":"Rentsch","year":"2014","unstructured":"Rentsch CA, Birkh\u00e4user FD, Biot C et al (2014) Bacillus calmette-guerin strain differences have an impact on clinical outcome in bladder cancer immunotherapy. Eur Urol 66(4):677\u2013688","journal-title":"Eur Urol"},{"key":"3774_CR35","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","volume":"65","author":"Brausi","year":"2014","unstructured":"Brausi M, Oddens J, Sylvester R et al (2014) Side effects of Bacillus Calmette-Guerin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol 65(1):69\u201376","journal-title":"Eur Urol"},{"key":"3774_CR36","doi-asserted-by":"crossref","unstructured":"Niedworok C (2015) Alternativen zur Zystektomie. Urologe (Epub ahesd of print)","DOI":"10.1007\/s00120-015-3775-6"},{"key":"3774_CR37","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00120-014-3649-3","volume":"54","author":"Rehme","year":"2014","unstructured":"Rehme C, Niedworok C, R\u00fcbben H, Vom Dorp F (2014) Non-muscle invasive bladder cancer: safety of postoperative EMDA-assisted instillation of mitomycin. Urologe A 54:235\u2013238","journal-title":"Urologe A"},{"key":"3774_CR38","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.eururo.2003.12.016","volume":"45","author":"Jakse","year":"2004","unstructured":"Jakse G, Algaba F, Malmstrom PU, Oosterlinck W (2004) A second-look TUR in T1 transitional cell carcinoma: why? Eur Urol 45:539\u2013546","journal-title":"Eur Urol"},{"key":"3774_CR39","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0022-5347(05)65969-1","volume":"166","author":"Dutta","year":"2001","unstructured":"Dutta SC, Smith JA Jr, Shappell SB et al (2001) Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol 166:490\u2013493","journal-title":"J Urol"},{"key":"3774_CR40","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1464-410X.2012.11391.x","volume":"112","author":"Sternberg","year":"2013","unstructured":"Sternberg IA, Keren Paz GE, Chen LY et al (2013) Role of immediate radical cystectomy in the treatment of patients with residual T1 bladder cancer on restaging transurethral resection. BJU Int 112:54\u201359","journal-title":"BJU Int"},{"key":"3774_CR41","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.eururo.2009.07.005","volume":"56","author":"Dalbagni","year":"2009","unstructured":"Dalbagni G, Vora K, Kaag M et al (2009) Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer. Eur Urol 56:903\u2013910","journal-title":"Eur Urol"},{"key":"3774_CR42","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/S0022-5347(05)67022-X","volume":"164","author":"Van","year":"2000","unstructured":"Van Der Meijden A, Sylvester R, Collette L et al (2000) The role and impact of pathology review on stage and grade assessment of stages Ta and T1 bladder tumors: a combined analysis of 5 European Organization for Research and Treatment of Cancer Trials. J Urol 164:1533\u20131537","journal-title":"J Urol"},{"key":"3774_CR43","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.juro.2006.03.038","volume":"176","author":"Hautmann","year":"2006","unstructured":"Hautmann RE, Gschwend JE, Petriconi RC de et al (2006) Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. J Urol 176:486\u2013492","journal-title":"J Urol"},{"key":"3774_CR44","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0022-5347(05)65756-4","volume":"166","author":"Herr","year":"2001","unstructured":"Herr HW, Sogani PC (2001) Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol 166:1296\u20131299","journal-title":"J Urol"},{"key":"3774_CR45","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2009.08.024","volume":"57","author":"Kulkarni","year":"2010","unstructured":"Kulkarni GS, Hakenberg OW, Gschwend JE et al (2010) An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. Eur Urol 57:60\u201370","journal-title":"Eur Urol"},{"key":"3774_CR46","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.juro.2006.08.070","volume":"177","author":"Herr","year":"2007","unstructured":"Herr HW, Donat SM, Dalbagni G (2007) Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy? J Urol 177:75\u201379","journal-title":"J Urol"},{"key":"3774_CR47","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.eururo.2011.10.029","volume":"62","author":"Palou","year":"2012","unstructured":"Palou J, Sylvester RJ, Faba OR et al (2012) Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guerin. Eur Urol 62:118\u2013125","journal-title":"Eur Urol"},{"key":"3774_CR48","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.eururo.2011.10.026","volume":"61","author":"Rhijn","year":"2012","unstructured":"Rhijn BW van, Kwast TH van der, Alkhateeb SS et al (2012) A new and highly prognostic system to discern T1 bladder cancer substage. Eur Urol 61:378\u2013384","journal-title":"Eur Urol"},{"key":"3774_CR49","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1111\/j.1464-410X.2012.11455.x","volume":"111","author":"Tilki","year":"2013","unstructured":"Tilki D, Shariat SF, Lotan Y et al (2013) Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with final stage T1 disease and negative lymph nodes after radical cystectomy. BJU Int 111:1215\u20131221","journal-title":"BJU Int"}],"container-title":["Der Urologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-015-3774-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00120-015-3774-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-015-3774-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T08:19:35Z","timestamp":1566461975000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00120-015-3774-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,25]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["3774"],"URL":"https:\/\/doi.org\/10.1007\/s00120-015-3774-7","relation":{},"ISSN":["0340-2592","1433-0563"],"issn-type":[{"value":"0340-2592","type":"print"},{"value":"1433-0563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,25]]}}}